Time to Confirmatory Study Initiation After Accelerated Approval of Cancer and Noncancer Drugs in the US

被引：3
|
作者：
Jazowski, Shelley A. [1 ,5 ]
Vaidya, Avi U. [1 ]
Donohue, Julie M. [2 ]
Dusetzina, Stacie B. [1 ,3 ]
Sachs, Rachel E. [4 ]
机构：
[1] Vanderbilt Univ, Sch Med, Dept Hlth Policy, Nashville, TN USA
[2] Univ Pittsburgh, Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA USA
[3] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[4] Washington Univ St Louis, Sch Law, St Louis, MO USA
[5] Vanderbilt Univ, Sch Med, Dept Hlth Policy, 2525 West End Ave,Ste 1200, Nashville, TN 37203 USA
来源：
JAMA INTERNAL MEDICINE | 2023年 / 183卷 / 07期
基金：
美国医疗保健研究与质量局;
关键词：
D O I：
10.1001/jamainternmed.2023.0777
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
This cross-sectional study examines and compares the time taken from the accelerated approval of cancer and noncancer drugs to the initiation of confirmatory studies in the US.
引用
收藏
页码：737 / 739
页数：3
相关论文
共 50 条
  • [31] Accelerated Approval for Cancer Drugs in the United States and the Clinical Evidence Required for Conversion to Regular Approval
    Kato, Satoshi
    Ono, Shunsuke
    JOURNAL OF PHARMACEUTICAL INNOVATION, 2024, 19 (05)
  • [32] Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval
    Liu, Ian T. T.
    Kesselheim, Aaron S.
    Cliff, Edward R. Scheffer
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 331 (17): : 1471 - 1479
  • [33] Cancer Rates over Time After Initiation of Overactive Bladder Drugs
    Kaye, James A.
    Margulis, Andrea V.
    Plana, Estel
    Calingaert, Brian
    Perez-Gutthann, Susana
    Arana, Alejandro
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 31 - 31
  • [34] Recent Trends in Medicaid Spending and Use of Drugs With US Food and Drug Administration Accelerated Approval
    Sachs, Rachel E.
    Gavulic, Kyle A.
    Donohue, Julie M.
    Dusetzina, Stacie B.
    JAMA HEALTH FORUM, 2021, 2 (10): : E213177
  • [35] Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration
    Naci, Huseyin
    Smalley, Katelyn R.
    Kesselheim, Aaron S.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (07): : 626 - 636
  • [36] Hurry up and wait: Is accelerated approval of new cancer drugs in the best interests of cancer patients?
    Schilsky, RL
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (20) : 3718 - 3720
  • [37] Accelerated Approval of Cancer Drugs: Improved Access to Therapeutic Breakthroughs or Early Release of Unsafe and Ineffective Drugs?
    Richey, Elizabeth A.
    Lyons, E. Alison
    Nebeker, Jonathan R.
    Shankaran, Veena
    McKoy, June M.
    Luu, Thanh Ha
    Nonzee, Narissa
    Trifilio, Steven
    Sartor, Oliver
    Benson, Al B., III
    Carson, Kenneth R.
    Edwards, Beatrice J.
    Gilchrist-Scott, Douglas
    Kuzel, Timothy M.
    Raisch, Dennis W.
    Tallman, Martin S.
    West, Dennis P.
    Hirschfeld, Steven
    Grillo-Lopez, Antonio J.
    Bennett, Charles L.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (26) : 4398 - 4405
  • [38] Drugs with FDA accelerated approval often have weak evidence, study finds
    Dyer, Owen
    BMJ-BRITISH MEDICAL JOURNAL, 2017, 357
  • [39] Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug Administration
    Tibau, Ariadna
    Ocana, Alberto
    Anguera, Georgia
    Seruga, Bostjan
    Templeton, Arnoud J.
    Barnadas, Agusti
    Amir, Eitan
    JAMA ONCOLOGY, 2016, 2 (06) : 744 - 750
  • [40] Analysis of cancer drugs receiving FDA's Accelerated Approval between 1992 and 2021
    Lim, Heeyeon
    Kim, Minji
    Kang, Geeyoon
    Ko, Minji
    Kim, Eunyoung
    JOURNAL OF PHARMACEUTICAL HEALTH SERVICES RESEARCH, 2024, 15 (03)
12345